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A study of children was conducted in 3 Central Asian
Republics. Approximately half of the Streptococcus pneu-
moniae isolates were serotypes included in available vac-
cine formulations. Approximately 6% of children carried
Haemophilus influenzae type b (Hib). Using pneumococcal
and Hib conjugate vaccines may decrease illness in the
Central Asian Republics.
S
treptococcus pneumoniae and Haemophilus influenzae
cause a large percentage of acute respiratory and inva-
sive bacterial infections throughout the world (1). Acute
respiratory infection is the leading cause of childhood
death in the Central Asian Republics of the former Soviet
Union (2,3), a region that includes Kazakhstan,
Uzbekistan, Turkmenistan, Tajikistan, and the Kyrgyz
Republic. These deaths occur despite the availability and
use of antimicrobial drugs throughout the former Soviet
Union (4,5).
To prevent illness from S. pneumoniae in the United
States, the 7-valent pneumococcal conjugate vaccine
(Prevnar, Wyeth Pharmaceuticals, Philadelphia, PA, USA)
was added to the routine infant immunization schedule in
2000. Prevnar contains S. pneumoniae serotypes 4, 6B, 9V,
14, 18C, 19F, and 23F. Higher valency formulations (9-,
11-, and 13-valent) are under evaluation. The 9-valent for-
mulation (including types 1 and 5) was successful in South
Africa (6) and The Gambia (7), and an 11-valent formula-
tion (including types 1, 3, 5, and 7F) is being studied in the
Philippines. An accelerated development and introduction
plan for pneumococcal conjugate vaccines for use in
developing countries is supported by the Global Alliance
for Vaccines and Immunization (www.preventpneumo-
nia.com).
H. influenzae type b (Hib) conjugate vaccines have
been recommended for infants in the United States since
1990. Widespread use of these vaccines has dramatically
reduced Hib invasive disease in both industrialized and
developing countries (8,9). The World Health Organization
(WHO) has recommended use of the Hib conjugate vac-
cine in regions of the world where the extent of Hib dis-
ease has been established. Prevalence of Hib invasive
disease must be assessed in countries in the Central Asian
Republics before introducing the Hib conjugate vaccine. 
Laboratory data to determine prevalence of S. pneumo-
niae and Hib are not collected in the Central Asian
Republics. To determine the benefits of using the pneumo-
coccal and Hib conjugate vaccines in these countries, we
conducted a nasopharyngeal swab survey of pediatric
patients to identify the most prevalent serotypes and peni-
cillin-resistance patterns of S. pneumoniae and to assess
the presence of Hib.
The Study
In January 1997, we obtained nasopharyngeal swabs
from a convenience sample of both ill and well children,
ages 2–59 months, who were visiting outpatient clinics in
Taraz City (formerly Djambul), Kazakhstan; Fergana,
Uzbekistan; and Osh, Kyrgyz Republic. Before swabs
were obtained, written parental consent was obtained in
Russian, Kazak, Kyrgyz, or Uzbek under a protocol
approved by a local institutional review board and the
Centers for Disease Control and Prevention (CDC).
Nasopharyngeal swab collection and pathogen isola-
tion have been described previously (1). Briefly, a flexi-
ble calcium alginate swab was inserted through the nares
to the nasopharynx, rotated ≈180°, and withdrawn. While
in the field, the swabs were first streaked on chocolate
agar (CA) plates containing bacitracin to isolate H.
influenzae, and then onto Trypticase soy 5% sheep blood
agar plates containing gentamicin to isolate S. pneumoni-
ae. All plates were brought back to the laboratory and
incubated appropriately. Pure H. influenzae cultures were
isolated and spread onto quad plates. Those colonies that
grew on only the XV and blood quadrants were consid-
ered to be H. influenzae and were saved on CA slants.
Suspected  S. pneumoniae colonies were streaked onto
conventional 5% sheep blood agar plates with an
optochin disk added. After appropriate incubation,
α-hemolytic isolates with an optochin inhibition zone
>14 mm were considered to be   S. pneumoniae and saved
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moniae were transported to CDC in Atlanta. Isolates of H.
influenzae were serotyped with Difco H. influenzae
serotype-specific rabbit antisera (BD, Sparks, MD, USA),
and S. pneumoniae isolates were serotyped with CDC-
prepared antiserum. S. pneumoniae cultures were tested
for antimicrobial susceptibility to penicillin with broth
dilution MIC testing by using the guidelines of the
Clinical and Laboratory Standards Institute (formerly
NCCLS) and customized MIC panels.
Results were similar in all 3 sites, so data were com-
bined. The method of isolate storage and transport resulted
in different survival rates among isolates (Tables 1 and 2).
Low rates of S. pneumoniae isolates among children
receiving antimicrobial drugs prevent any conclusions
about that group. Among S. pneumoniae and H. influenzae
isolates, survival was negatively associated with duration
of storage. Among S. pneumoniae isolates, survival was
positively associated with increasing age. However, the
lack of any trends in Hib colonization and S. pneumoniae
nonsusceptibility by age and duration of storage suggests
that differential survival did not produce bias. 
Of 630 children swabbed, 375 (59%) were colonized
with S. pneumoniae. Of the 375 isolates, 224 S. pneumo-
niae isolates were available for susceptibility testing and
serotyping. Of the 224 isolates, 54 (24%) were nonsus-
ceptible to penicillin. The 9 most common serotypes
in decreasing order were 19F (17% of isolates), 6B
(15%), 6A (9%), 14 (6%), 23B (4%), 19A (3%), 23F
(3%), 18C (2%), and 4 (2%). These accounted for 61% of
all isolates.
In our sample, the 7-valent pneumococcal conjugate
vaccine would cover 47% of pneumococcal isolates, the 9-
valent would cover 48%, and the 11-valent would cover
51%. Of all the serotypes covered in these vaccines,
serotypes 6B, 14, 19F, and 23F account for all nonsuscep-
tible strains. Because all 3 vaccines contain these 4
serotypes, each vaccine would cover 33 (61%) of 54 non-
susceptible isolates of S. pneumoniae. An additional 13%
of nonsusceptible strains are vaccine-related (strains 6A[4
of 54, 7%] and 23B [3 of 54, 6%]).
Of the 630 children from whom nasopharyngeal swabs
were obtained, 357 (57%) were carrying H. influenzae. Of
the 300 isolates available for serotyping, 34 (11%) were
Hib. When Hib carriage is determined by multiplying the
percentage of children colonized with H. influenzae times
the percentage of Hib among all H. influenzae isolates test-
ed, the carriage rate is 6% (Table 2).
Conclusions
Our survey showed that most children in these Central
Asian Republics were colonized with at least 1 potential
respiratory pathogen. Approximately half of the S. pneu-
moniae isolates and more than half of the penicillin-non-
susceptible  S. pneumoniae isolates are included in the
available pneumococcal conjugate vaccine formulations.
Approximately 6% of the children in this convenience
sample were carrying Hib.
The colonization rate of Hib found in our study is sim-
ilar to rates observed in industrialized populations before
Hib conjugate vaccines were widely used. Carriage rates
for Hib before widespread vaccination in Finland, the
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(10–13). In these countries, introduction of the Hib vaccine
virtually eliminated Hib invasive disease (13).
Assessing the prevalence of disease due to specific res-
piratory pathogens is difficult; blood cultures are insensi-
tive, and other diagnostic tests are not specific.
Nasopharyngeal colonization surveys of groups of chil-
dren identify the predominant organisms circulating in the
community and the presence or absence of antimicrobial-
drug resistance. The presence of S. pneumoniae serotypes
found in the pneumococcal conjugate vaccine suggests this
vaccine may decrease some illness from acute respiratory
infection. The experience in other countries with similar
prevaccination Hib nasopharyngeal carriage rates suggests
that the Hib conjugate vaccine may also decrease illness.
These findings may be helpful in the decision-making
process regarding the value of introducing conjugate vac-
cines for Hib and pneumococcal disease prevention.
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